Covered recipient · General Payments record
TAREK MOURIS MEKHAIL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$270,088.32
215 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $211,969.50 | 84 |
| Consulting Fee | $33,292.50 | 18 |
| Travel and Lodging | $21,962.82 | 68 |
| Food and Beverage | $2,843.42 | 43 |
| Education | $20.08 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $106,890.30 | 72 |
| E.R. Squibb & Sons, L.L.C. | $48,414.59 | 35 |
| Lilly USA, LLC | $46,450.92 | 53 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,830.00 | 7 |
| Genentech USA, Inc. | $13,050.34 | 8 |
| Amgen Inc. | $12,840.73 | 13 |
| Regeneron Healthcare Solutions, Inc. | $8,045.90 | 6 |
| Novartis Pharmaceuticals Corporation | $5,240.00 | 1 |
| GENZYME CORPORATION | $5,144.53 | 4 |
| Janssen Scientific Affairs, LLC | $4,430.00 | 5 |
| Daiichi Sankyo Inc. | $3,172.50 | 2 |
| Exelixis Inc. | $1,980.00 | 1 |
| EMD Serono, Inc. | $500.00 | 1 |
| Seagen Inc. | $58.18 | 4 |
| Janssen Biotech, Inc. | $20.25 | 1 |
| Gilead Sciences, Inc. | $11.92 | 1 |
| PFIZER INC. | $8.16 | 1 |
Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TAREK MOURIS MEKHAIL
NPI 1447214911 · CMS profile ID 20341
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447214911?year=2021&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447214911?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447214911?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447214911?year=2021&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
215 matching records · $270,088.32 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–215 of 215.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $2,925.00 | 03/20/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820083669 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,925.00 | 03/20/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820083673 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 02/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820083665 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 02/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834321901 | CMS |
| AstraZeneca Pharmaceuticals LP | $165.60 | 02/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834335103 | CMS |
| AstraZeneca Pharmaceuticals LP | $46.76 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834346565 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,450.00 | 02/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834320937 | CMS |
| E.R. Squibb & Sons, L.L.C. | $600.00 | 02/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783631717 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 02/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820083661 | CMS |
| GENZYME CORPORATION | $822.00 | 02/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843490475 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 01/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820083657 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 01/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834341073 | CMS |
| AstraZeneca Pharmaceuticals LP | $89.60 | 01/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834321771 | CMS |
| AstraZeneca Pharmaceuticals LP | $107.86 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834335897 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 01/06/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347965 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,768,828.32 | 247 |
| PY2024 | Principal investigator | $1,170,325.71 | 109 |
| PY2023 | Principal investigator | $1,396,237.27 | 80 |
| PY2022 | Principal investigator | $1,923,901.07 | 96 |
| PY2021 | Recipient | $1,270.00 | 2 |
| PY2021 | Principal investigator | $1,557,403.99 | 90 |
| PY2020 | Recipient | $600.00 | 1 |
| PY2020 | Principal investigator | $747,855.68 | 78 |
| PY2019 | Recipient | $4,912.54 | 1 |
| PY2019 | Principal investigator | $441,978.21 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
247 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $269.30 | 12/31/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407 | No dispute reported | 06/30/2026 | 1232926003 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,540.72 | 12/31/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232926843 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,970.54 | 12/31/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927511 |
| Principal investigator 1 | Amgen Inc. | $1,000.00 | 12/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) | No dispute reported | 06/30/2026 | 1246638010 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,536.00 | 12/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175391787 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $952.00 | 12/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199913191 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.84 | 12/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343861 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,181.00 | 12/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,155.00 | 12/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $476.00 | 12/10/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343837 |
| Principal investigator 1 | Amgen Inc. | $103.04 | 12/08/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH INSTITUTE | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309) | No dispute reported | 06/30/2026 | 1246649902 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $8,671.31 | 12/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199913185 |
| Principal investigator 1 | PFIZER INC. | $4,401.00 | 12/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228746792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,465.00 | 12/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343855 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343847 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 12/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343851 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343857 |
| Principal investigator 1 | Genmab U.S., Inc. | $11,272.50 | 11/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921632 |
| Principal investigator 1 | Genmab U.S., Inc. | $360.45 | 11/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $257.00 | 11/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391386 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $476.00 | 11/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343679 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,117.00 | 11/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343681 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $4,195.06 | 11/18/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199913187 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 11/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921635 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 11/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921639 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,530.00 | 11/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175391640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,955.00 | 11/05/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343841 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,924.00 | 11/05/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343843 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,102.00 | 11/05/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343849 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,145.00 | 11/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343667 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $936.00 | 11/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,117.00 | 11/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,117.00 | 11/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $476.00 | 10/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 10/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391781 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $476.00 | 10/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199913189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343663 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36.50 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343675 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343683 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $93.00 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343687 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.70 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343689 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $210.00 | 10/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391551 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,622.66 | 10/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921620 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,070.56 | 10/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921624 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 10/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $476.00 | 10/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343839 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $600.00 | 10/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343845 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $11,248.17 | 10/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199913183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,015.00 | 10/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343831 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 10/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343835 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,210.00 | 10/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343859 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343829 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.40 | 10/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343833 |
| Principal investigator 1 | Janssen Research & Development, LLC | $502.00 | 09/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,098.00 | 09/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 09/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,117.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343597 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,817.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343599 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,742.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343601 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,499.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343603 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,612.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343605 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,426.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,714.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,817.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,426.00 | 09/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343629 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 09/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228760049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $600.00 | 09/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343607 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 09/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175391592 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343815 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,100.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343817 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343819 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,322.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343821 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,440.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343823 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 09/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343825 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,729.27 | 09/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913169 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,827.00 | 09/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175391658 |
| Principal investigator 1 | Genmab U.S., Inc. | $10,867.98 | 08/27/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921585 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,702.75 | 08/27/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921600 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 08/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391509 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 08/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921573 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,969.35 | 08/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921582 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,676.00 | 08/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921596 |
| Principal investigator 1 | Genmab U.S., Inc. | $17,505.45 | 08/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921604 |
| Principal investigator 1 | PFIZER INC. | $4,401.00 | 08/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228788773 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343635 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343637 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343639 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343643 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343651 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343655 |
| Principal investigator 1 | Genmab U.S., Inc. | $8,915.40 | 08/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921616 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $12,222.21 | 08/05/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913167 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343781 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $83.40 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343783 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343785 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $618.60 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343787 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343789 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343791 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.75 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343793 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343795 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343797 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343799 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343801 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343803 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,932.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343805 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343807 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,258.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343809 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,118.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343811 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,282.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343813 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343827 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921592 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,702.20 | 08/04/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921608 |
| Principal investigator 1 | Genmab U.S., Inc. | $708.75 | 07/29/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921589 |
| Principal investigator 1 | Amgen Inc. | $378,576.80 | 07/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309) | No dispute reported | 06/30/2026 | 1246638016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,840.00 | 07/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391452 |
| Principal investigator 1 | Genmab U.S., Inc. | $22,545.00 | 07/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921577 |
| Principal investigator 1 | Genmab U.S., Inc. | $959.37 | 07/25/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921612 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,670.00 | 07/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391634 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $476.00 | 07/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913165 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343573 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343575 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $91.25 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343593 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343595 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343609 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343611 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343613 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,329.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343579 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343581 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $750.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,500.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343585 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22,700.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 07/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-188 | No dispute reported | 06/30/2026 | 1223343591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,433.00 | 07/01/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175391726 |
| Principal investigator 1 | Genmab U.S., Inc. | $830.25 | 06/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 06/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 06/23/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391580 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 06/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921559 |
| Principal investigator 1 | Genmab U.S., Inc. | $32,603.94 | 06/19/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921562 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13,841.00 | 06/18/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,129.00 | 06/16/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175391770 |
| Principal investigator 1 | PFIZER INC. | $4,651.00 | 06/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228776706 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $72.90 | 06/13/2025 | Covered Recipient Teaching Hospital ADVENTHEALTH ORLANDO | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1223263394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 06/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343771 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 06/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343773 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,500.00 | 06/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343775 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,329.00 | 06/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343777 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 06/02/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343779 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,900.00 | 05/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 05/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391765 |
| Principal investigator 1 | PFIZER INC. | $1,766.00 | 05/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228782675 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,576.00 | 05/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913177 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $4,195.06 | 05/12/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913173 |
| Principal investigator 1 | Genmab U.S., Inc. | $8,888.40 | 05/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,563.00 | 05/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $420.00 | 04/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391539 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $3,549.20 | 04/28/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236530168 |
| Principal investigator 1 | PFIZER INC. | $673.65 | 04/26/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228780270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 04/18/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391574 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,082.71 | 04/17/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921554 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,676.00 | 04/16/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913179 |
| Principal investigator 1 | PFIZER INC. | $4,401.00 | 04/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228797258 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $638.68 | 04/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913171 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $476.00 | 04/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913181 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,907.00 | 04/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na ve, metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor proportion score TPS greater tha | No dispute reported | 06/30/2026 | 1232936786 |
| Principal investigator 1 | Amgen Inc. | $5,276.00 | 04/07/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting | No dispute reported | 06/30/2026 | 1246638024 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 03/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921534 |
| Principal investigator 1 | Genmab U.S., Inc. | $179,670.98 | 03/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921543 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,155.00 | 03/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391481 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $6,425.33 | 03/18/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913159 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $9,845.13 | 03/18/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22,700.00 | 03/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343863 |
| Principal investigator 1 | PFIZER INC. | $438.75 | 03/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228788643 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 03/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343695 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343697 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343711 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343713 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343715 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343717 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343719 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.70 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343721 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343723 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343725 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343727 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343729 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343733 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343735 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343737 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343739 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343741 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343745 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343747 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343749 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343751 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343753 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343755 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $48.35 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343757 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $37.35 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343759 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343763 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $255.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.60 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343767 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | DS7300-189 | No dispute reported | 06/30/2026 | 1223343769 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,047.16 | 02/24/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927341 |
| Principal investigator 1 | Genmab U.S., Inc. | $360.45 | 02/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921539 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,670.00 | 02/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391471 |
| Principal investigator 1 | Genentech, Inc. | $2,134.30 | 02/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | My Pathway | No dispute reported | 06/30/2026 | 1211539649 |
| Principal investigator 1 | PFIZER INC. | $517.05 | 02/13/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA | No dispute reported | 06/30/2026 | 1228750011 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $18,090.00 | 02/11/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913163 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,354.91 | 02/03/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199913157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $210.00 | 01/30/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391418 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $129,309.36 | 01/22/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III | No dispute reported | 06/30/2026 | 1185549287 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,485.00 | 01/20/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175391653 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,665.72 | 01/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) | No dispute reported | 06/30/2026 | 1185549285 |
| Principal investigator 1 | AstraZeneca UK Limited | $27,993.96 | 01/15/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY | No dispute reported | 06/30/2026 | 1185549293 |
| Principal investigator 1 | AstraZeneca UK Limited | $28,414.85 | 01/14/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) | No dispute reported | 06/30/2026 | 1185549289 |
| Principal investigator 1 | Genmab U.S., Inc. | $476.00 | 01/09/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235921546 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $363,268.25 | 01/08/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185549291 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $13,611.40 | 01/06/2025 | Covered Recipient Teaching Hospital Adventhealth Orlando | A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) | No dispute reported | 06/30/2026 | 1236001869 |